Editor-in-Chief Ufuk Demirkılıç Frequency Quarterly Abbreviation Damar Cer Derg Publisher Turkish National Vascular and Endovascular Surgery Society ISSN 1301 - 1839 E-ISSN 2149 - 1259


Turkish Journal of Vascular Surgery 0 , Vol 0 , Issue 0
Protective effect of cilostazol and rosuvastatin on acute kidney injury-induced lung injury using TNF-a and HIF-1a immunoreactivities
Şahin İşcan1, İsmail Yürekli1, Fatmagül Kuşku Çabuk2, Habib Çakır1, Börteçin Eygi1, Köksal Dönmez1, Ali Gürbüz2
1Department of Cardiovascular Surgery, İzmir Katip Çelebi University Atatürk Training and Research Hospital, İzmir, Turkey
2Department of Pathology, İstanbul Bilim University, Gayrettepe Florence Nightingale Hospital, İstanbul, Turkey
DOI : 10.9739/tjvs.2018.185 Objectives: This study aims to investigate the effects of preoperative cilostazol and rosuvastatin therapy on isolated kidney ischemia/reperfusison (I/R) injury-induced remote lung reperfusion injury in an experimental model.

Materials and methods: A total of 35 female Sprague-Dawley rats were randomly divided into five groups (n=7). Median laparotomy and a 45-min bilateral kidney ischemia were performed. Oral medications were administered three days before the surgical intervention (20 mg/kg cilostazol, 10 mg/kg rosuvastatin, and 20 mg/kg cilostazol+10 mg/kg rosuvastatin). Lung tissue samples were extracted one day after surgery. Tumor necrosis factor-a (TNF-a) and hypoxiainduced factor-1a (HIF-1a) antibodies were used for immunohistochemical examinations of lung tissues cross-sections.

Results: TNF-a immunoreactivities in I/R+cilostazol, I/R+rosuvastatin and I/R+cilostazol+rosuvastatin groups were found to be decreased significantly, compared to I/R group (p<0.05). Lung TNF-a immunoreactivities in I/R+rosuvastatin, and I/R+cilostazol+rosuvastatin groups was found to be increased significantly, compared to control group (p<0.05). HIF-1a immunoreactivities in I/R+cilostazol, I/R+rosuvastatin, and I/R+cilostazol+rosuvastatin groups were found to be decreased significantly, compared to I/R group (p<0.05). HIF-1a immunoreactivites amoung I/R+cilostazol, I/R+rosuvastatin and I/R+cilostazol+rosuvastatin groups were found similar, compared to control group (p>0.05).

Conclusion: Cilostazol and rosuvastatin have prophylactic effects on kidney I/R injury-induced lung reperfusion injury. Their single or combined use for peripheral arterial diseases may be beneficial for patients on perioperative period. Keywords : Ischemia/reperfusion injury; kidney; lung